TITLE

FDA Actions

AUTHOR(S)
Elliott, William T.
PUB. DATE
June 2009
SOURCE
Clinical Cardiology Alert;Jun2009 Pharmacology Watch, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents an update on U.S. Food and Drug Administration (FDA) actions in 2009. A morning after pill called Plan B from Duramed Pharmaceuticals will be available to women age 17 and older without a prescription following a court order directing the FDA to evaluate clinical data to determine whether there should be any age restrictions on the use of the drug. The FDA also approved a tumor-necrosis factor (TNF)-alpha blocker monoclonal antibody Golimunab from Centocor Ortho Biotech for rheumatoid arthritis treatment and other diseases.
ACCESSION #
41038426

 

Related Articles

  • Centocor Ortho Biotech's Simponi Gains Approval. Young, Donna // BioWorld Today;4/27/2009, Vol. 20 Issue 79, p2 

    The article reports on the approval of Simponi, an antitumor necrosis factor (TNF)-alpha therapy of Centocor Ortho Biotech Inc., by the U.S. Food and Drug Administration (FDA). The therapy is a patient-administered monthly treatment for moderate to severe active rheumatoid arthritis, active...

  • Simponi.  // Pharmaceutical Representative;Jul2009, Vol. 39 Issue 7, p11 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Simponi (golimumab) from Centocor Ortho Biotech Inc. It notes that the drug treats rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis. It is considered as the first...

  • FDA Actions. Elliott, William T. // Primary Care Reports;Jun2009 Pharmacology Watch, p2 

    The article reports on several U.S. Food and Drug Administration drug approval as of June 2, 2009. A U.S. district judge ruled in March for the drug Plan B, the so-called "morning after pill" to be made available to women age 17. The agency has approved golimumab, a tumor necrosis factor-alpha...

  • J&J: Simponi's triple US approval could be first step towards blockbuster status.  // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p21 

    In this article the author discusses the approval of Simponi (golimumab) from Centocor Ortho Biotech Inc. by the U.S. Food and Drug Administration (FDA). It is a new tumor necrosis factor (TNF) inhibitor for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. He mentions that...

  • Centocor Ortho Set to Roll Out Stelara.  // Chain Drug Review;10/26/2009, Vol. 31 Issue 18, p74 

    The article reports on the approval of Stelara drug from Centocor Ortho Biotech Inc. by the U.S. Food and Drug Administration. Stelara is a biologic product for adults who have a moderate to severe form of psoriasis. According to Centocor, the drug will treat psoriasis by blocking the action of...

  • New biologic.  // Formulary;Nov2009, Vol. 44 Issue 11, p320 

    The article presents information on the drug Stelara by Centocor Ortho Biotech Inc. It is a human monoclonal antibody approved for treatment of plaque psoriasis. The clinical development program for this drug included around 2200 patients and two important phase three trials that served as the...

  • FDA Approves Biologic to Treat Psoriasis.  // BioPharm International;Nov2009, Vol. 23 Issue 11, p14 

    The article reports on the U.S. Food and Drug Administration's (FDA's) approval of Stelara from Centocor Ortho Biotech Inc. to treat psoriasis. It notes that the drug blocks the action of two proteins contributing to the overproduction of skin cells and inflammation. It points out that FDA...

  • FDA approves tocilizumab to treat rheumatoid arthritis. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;2/15/2010, Vol. 67 Issue 4, p254 

    The article offers information on the U.S. Food and Drug Administration (FDA) approving the of tocilizumab drug. It reports that the drug treats rheumatoid arthritis and is marketed by Genentech Inc. which made the announcement on January 8. The company said that the drug is first monoclonal...

  • Stelara for psoriasis.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA8 

    The article reports on the approval of monoclonal antibody Stelara from Centocor Ortho Biotech Inc. in the treatment of moderate-to-severe psoriasis. It mentions that the drug is indicated to patients ages 18 years old and above who are advised to have phototherapy or systemic therapy. It also...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics